1-3 of 3
Zhiyu Liang
Close
Sort by
Journal Articles

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huilai Zhang, Keshu Zhou, Ying Cheng, Liling Zhang, Haiyan Yang, Liqun Zou, Junning Cao, Huiqiang Huang, Ye Guo, Zhao Wang, Sha Huang, Zhiyu Liang, Hui Yao, Haiyi Guo, Yiqian Fang, Hongjie Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3750–3752.
https://doi.org/10.1182/blood-2022-155979
Published: 2022
Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela McKay, Henry Chan, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter J. Browett, Xiaoyan Ke, Craig A. Portell, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Journal: Blood
Blood (2022) 140 (Supplement 1): 573–576.
https://doi.org/10.1182/blood-2022-163371
Published: 2022
Journal Articles

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

Caixia Li, Jia Wei, Keshu Zhou, Peng Liu, He Huang, Fei Li, Yujun Dong, Qingqing Cai, Shenmiao Yang, Xinyou Zhang, Hui Zhou, Lu Zhang, Zaixing Shi, Zhiyu Liang, Binghao Wu, Depei Wu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6717–6718.
https://doi.org/10.1182/blood-2022-171046
Published: 2022